Colorectal Cancer Alliance announces funding recipients for colon and rectal cancer research needs

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print

Colorectal Cancer Alliance is providing a total of $625,000 in grants to four researchers, including one advancing personalized treatment options for rectal cancer patients and three seeking to understand the root cause of rising colorectal cancer rates in patients under age 50.

Grant recipients include:

  • J. Joshua Smith of Memorial Sloan Kettering Cancer Center who will build on his previous research using patient-specific rectal cancer organoids to grow human-specific rectal cancer models in mice as a platform for developing personalized treatments.

  • Robin B. Mendelson of Memorial Sloan Kettering Cancer Center who will describe the gut microbiome of patients under age of 50, comparing them to the microbiomes of older people with colorectal cancer and the microbiomes of younger healthy people.

  • Joshua Meyer of Fox Chase Cancer Center who will describe the genetic and genomic features of colorectal cancer patients young and old, and thoroughly characterize the biology of young-onset colorectal in patients under 50 years old.

  • Rosa Maria Munoz Xicola of the Yale School of Medicine will provide essential knowledge on how the APC-negative subset of colorectal cancers develop, which is crucial in the development of effective early detection tests and treatments. Xicola will also investigate whether the APC-negative subset disproportionately affects African Americans and young people.

The Colorectal Cancer Alliance is now accepting applications for its prevention research grants. The application deadline is 11:59 p.m., Monday, March 18, 2019.

Table of Contents

YOU MAY BE INTERESTED IN

For nearly 25 years, business executive Lou Weisbach and urologist Richard J. Boxer have argued that finding the money to finance the cures for devastating diseases is not as difficult as it appears. To start finding the cures, the U.S. Department of the Treasury needs to issue some bonds—$750 billion worth. Next, you hire CEOs—one...

There is general agreement that the United States spends too much on health care, especially on pharmaceuticals.  But what we spend on drugs is not simply a function of price. If eggs double in price, people can simply cut the number of eggs they eat in half.  Simply stated, cost is the product of (price per unit times the number of units purchased). 
What did President Richard M. Nixon and Senator Edward M. Kennedy have in common? They each played a pivotal role in the passage of the National Cancer Act signed by Nixon on Dec. 23, 1971. The NCA established the National Cancer Program authorizing the initial investment in the NCI-designated Cancer Centers Program. 
When I first proposed targeting PCNA (proliferating cell nuclear antigen) as a therapeutic approach, the response I got was: “No one will ever make a drug against PCNA. It’s undruggable.” The protein lacks enzymatic activity, has a disordered region, and binds to over 200 other proteins within the cell. From a traditional drug development perspective, these characteristics made PCNA an impossible target.

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login